Scott Rocklage is a highly revered health management expert and leader and a doctorate holder. He has multiple involvements in ground breaking inventions in the medical field and currently holds more than 30 patents.
Scott publicizes his concepts in various studies in articles and peer-reviewed works, which currently amount to 100 in a count. Scott is the managing partner of 5 AM Ventures since he received his promotion in 2004 after working as a partner for one year. He was at the fore front of developing three FDA-approved drugs, Cubicin, Omniscan, and Teslascan.
Apart from his involvement at 5 AM Ventures, Scott Rocklage was the former chief executive officer and chairman of Cubist Pharmaceuticals, ex-president and executive officer of Nycomed Salutar and various R&D roles at Catalytica and Salutar. Scott worked with Cidara, Kinestral, and Rennovia as a member of the Council of boards. Read more: Scott Racklage | Crunchbase
His vast experience in addition to his world-status education affords him the right equipment to conduct revolutionary projects. Scott has an undergraduate degree in chemistry from the University of California and a doctorate from the Massachusetts Institute of Technology.
Scott Rocklage’s entrepreneurial path and scientifically inclined career are built on his courageous attitude in life. Scott takes measures risks in putting out forthcoming products and conclusions which go a long way in helping patients.
He values his team members and stated that he depends on the professional input of scientists, managers, and physicians who play a major role in medical works. Experience taught the doctor that having a competitive team is the first priority when looking to produce consistently excellent quality in a timely fashion.
Scott Rocklage’s insight in 5 AM Venture’s name branding is an accurate representation of the firm’s goals and values. He explains that five in the morning is an early hour to start the day with a high note, synonymous to the firm’s ambition to stay ahead of the curve in the cancer research field.
Scott and his team have a specialty in studying cell mutations to customize cancer treatment according to specific genotypes. He spends his time working closely with the team and holding meetings with partners to ascertain successful completion of projects.
Learn more about Scott Rocklage: http://www.rennovia.com/team/scott-m-rocklage/ and http://www.thestylemaponline.com/the-amazing-career-of-scott-rocklage-of-5am-ventures/